- Home
- TCMD vs YMAB Comparison
TCMD vs YMAB Comparison
Compare TCMD & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCMD
- YMAB
- Stock Information
- Founded
- TCMD 1995
- YMAB 2015
- Country
- TCMD United States
- YMAB United States
- Employees
- TCMD N/A
- YMAB N/A
- Industry
- TCMD Medical/Dental Instruments
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TCMD Health Care
- YMAB Health Care
- Exchange
- TCMD Nasdaq
- YMAB Nasdaq
- Market Cap
- TCMD 235.5M
- YMAB 192.4M
- IPO Year
- TCMD 2016
- YMAB 2018
- Fundamental
- Price
- TCMD $9.96
- YMAB $4.36
- Analyst Decision
- TCMD Hold
- YMAB Buy
- Analyst Count
- TCMD 3
- YMAB 11
- Target Price
- TCMD $16.00
- YMAB $17.55
- AVG Volume (30 Days)
- TCMD 211.1K
- YMAB 202.0K
- Earning Date
- TCMD 08-04-2025
- YMAB 08-11-2025
- Dividend Yield
- TCMD N/A
- YMAB N/A
- EPS Growth
- TCMD N/A
- YMAB N/A
- EPS
- TCMD 0.66
- YMAB N/A
- Revenue
- TCMD $293,164,000.00
- YMAB $88,658,000.00
- Revenue This Year
- TCMD $7.96
- YMAB N/A
- Revenue Next Year
- TCMD $8.53
- YMAB $15.15
- P/E Ratio
- TCMD $15.15
- YMAB N/A
- Revenue Growth
- TCMD 5.96
- YMAB 4.92
- 52 Week Low
- TCMD $8.61
- YMAB $3.55
- 52 Week High
- TCMD $21.10
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- TCMD 43.95
- YMAB 45.29
- Support Level
- TCMD $9.80
- YMAB $4.10
- Resistance Level
- TCMD $10.32
- YMAB $4.62
- Average True Range (ATR)
- TCMD 0.30
- YMAB 0.29
- MACD
- TCMD 0.03
- YMAB -0.04
- Stochastic Oscillator
- TCMD 27.27
- YMAB 20.73
About TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.